Biotech partnership may lead to merger

Two privately held Vancouver biotech firms have entered a strategic partnership that could lead to an eventual merger. Zymeworks Inc has made an equity investment in Kairos Therapeutics Inc — a spin off of the Centre for Drug Research and Development. Zymeworks specializes in bi-specific and multi-specific anybodies while Cairos discovers and develops antibody drug conjugates. The partnership will allow the companies to explore the advantages of a merger on accelerating their respective platforms, resources and pipelines....